1. Fabrication and characterization of a new eco-friendly sulfonamide-chitosan derivative with enhanced antimicrobial and selective cytotoxicity properties.
- Author
-
Ibrahim AG, Hamodin AG, Fouda A, Eid AM, and Elgammal WE
- Subjects
- Humans, Candida albicans drug effects, Staphylococcus aureus drug effects, Escherichia coli drug effects, Spectroscopy, Fourier Transform Infrared, Cell Survival drug effects, X-Ray Diffraction, MCF-7 Cells, Chitosan chemistry, Chitosan pharmacology, Sulfonamides pharmacology, Sulfonamides chemistry, Microbial Sensitivity Tests, Anti-Infective Agents pharmacology, Anti-Infective Agents chemistry
- Abstract
Chitosan (CH) exhibits low antimicrobial activity. This study addresses this issue by modifying the chitosan with a sulfonamide derivative, 3-(4-(N,N-dimethylsulfonyl)phenyl)acrylic acid. The structure of the sulfonamide-chitosan derivative (DMS-CH) was confirmed using Fourier transform infrared spectroscopy and Nuclear magnetic resonance. The results of scanning electron microscopy, thermal gravimetric analysis, and X-ray diffraction indicated that the morphology changed to a porous nature, the thermal stability decreased, and the crystallinity increased in the DMS-CH derivative compared to chitosan, respectively. The degree of substitution was calculated from the elemental analysis data and was found to be moderate (42%). The modified chitosan exhibited enhanced antimicrobial properties at low concentrations, with a minimum inhibitory concentration (MIC) of 50 µg/mL observed for B. subtilis and P. aeruginosa, and a value of 25 µg/mL for S. aureus, E. coli, and C. albicans. In the case of native chitosan, the MIC values doubled or more, with 50 µg/mL recorded for E. coli and C. albicans and 100 μg/mL recorded for B. subtilis, S. aureus, and P. aeruginosa. Furthermore, toxicological examinations conducted on MCF-7 (breast adenocarcinoma) cell lines demonstrated that DMS-CH exhibited greater toxicity (IC50 = 225.47 μg/mL) than pure CH, while still maintaining significant safety limits against normal lung fibroblasts (WI-38). Collectively, these results suggest the potential use of the newly modified chitosan in biomedical applications., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF